This multicenter, prospective observational cohort study evaluated health-related quality of life (HR-QoL), psychological distress, and fatigue in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223. Patients who discontinued radium-223 therapy showed worse HR-QoL, psychological distress, and fatigue at baseline and experienced frequent deterioration over time compared to those who completed therapy. Opioid use, low hemoglobin, and high alkaline phosphatase levels before treatment predicted HR-QoL deterioration.
Publisher
Prostate Cancer and Prostatic Diseases
Published On
Jul 08, 2022
Authors
Maarten J. van der Doelen, Irma M. Oving, Dirk N. J. Wyndaele, Jean-Paul van Basten, Frederik Terheggen, Addy C. M. van de Luijtgaarden, Wim J. G. Oyen, W. Dick van Schelven, Franchette van den Berkmortel, Niven Mehra, Marcel J. R. Janssen, Judith B. Prins, Winald R. Gerritsen, José A. E. Custers, Inge M. van Oort
Tags
mCRPC
HR-QoL
psychological distress
fatigue
radium-223
treatment discontinuation
predictive factors
Related Publications
Explore these studies to deepen your understanding of the subject.
